Unlocking the EGFR-mediated epitranscriptome: A pathway to novel therapies

Jovanka Gencel-Augusto; Trever G Bivona

doi:10.1016/j.molcel.2023.10.044

Unlocking the EGFR-mediated epitranscriptome: A pathway to novel therapies

Mol Cell. 2023 Dec 7;83(23):4199-4201. doi: 10.1016/j.molcel.2023.10.044.

Authors

Jovanka Gencel-Augusto¹, Trever G Bivona²

Affiliations

¹ Department of Medicine, University of California, San Francisco (UCSF), San Francisco, CA 94158, USA; UCSF Hellen Diller Comprehensive Cancer Center, San Francisco, CA 94158, USA.
² Department of Medicine, University of California, San Francisco (UCSF), San Francisco, CA 94158, USA; UCSF Hellen Diller Comprehensive Cancer Center, San Francisco, CA 94158, USA; Chan-Zuckerberg Biohub, San Francisco, CA 94158, USA. Electronic address: trever.bivona@ucsf.edu.

PMID: 38065059
DOI: 10.1016/j.molcel.2023.10.044

Abstract

In this issue, Lv et al.¹ explore EGFR-driven epitranscriptomic reprogramming in glioblastoma, revealing the pivotal role of the EGFR-ALKBH5-GCLM axis in ferroptosis protection. Their findings offer mechanistic insight and therapeutic strategies involving novel combination targets to enhance tumor responses.

Publication types

Comment

MeSH terms

Brain Neoplasms* / genetics
Brain Neoplasms* / pathology
ErbB Receptors* / genetics
ErbB Receptors* / metabolism
Glioblastoma* / genetics
Glioblastoma* / metabolism
Humans

Substances

EGFR protein, human
ErbB Receptors